2023 World Conference on Lung Cancer (Posters)-EP06.06. High Circulating Activin a Plasma Level Is Associated with Advanced Tumor Stage and Poor Prognosis in Lung Squamous Cell Cancer Patients

EP06.06. High Circulating Activin a Plasma Level Is Associated with Advanced Tumor Stage and Poor Prognosis in Lung Squamous Cell Cancer Patients - PDF(Slides)

Back to course

Pdf Summary

A recent study has found that high levels of Activin A (ActA) in the bloodstream are associated with more advanced stages of lung squamous cell carcinoma (LUSC) and poorer survival rates in treatment-naive patients. Researchers measured ActA concentrations in plasma samples from 128 LUSC patients and 73 controls, and found that ActA levels were significantly higher in patients with LUSC compared to controls. These levels also correlated with advanced tumor stage and specific tumor characteristics such as T, N, and M stages. Patients with ActA levels above a certain threshold had significantly worse overall and disease-free survival rates.<br /><br />Furthermore, multivariate analysis revealed that high ActA levels were an independent predictor of shorter overall and disease-free survival. The study also developed a score that combined ActA levels with C-reactive protein (CRP) as a prognostic indicator for survival in LUSC patients. The researchers suggest that measuring ActA levels in the bloodstream could help identify patients with advanced stages of LUSC and serve as a prognostic parameter.<br /><br />Lung squamous cell carcinoma is a type of lung cancer that is associated with a poor prognosis and limited treatment options. Dysregulation of ActA has been observed in various types of cancers. The researchers conducted this study to determine the diagnostic and prognostic significance of ActA in LUSC. The findings suggest that ActA could be a potential biomarker for LUSC and may help guide treatment decisions and improve patient outcomes. Further research is needed to fully understand the role of ActA in LUSC and its potential as a therapeutic target.

Asset Subtitle

Mir Alireza Hoda

Meta Tag

Speaker Mir Alireza Hoda

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

Activin A

ActA

lung squamous cell carcinoma

LUSC

survival rates

treatment-naive patients

tumor stage

tumor characteristics

C-reactive protein

prognostic indicator